DMTs such as BCDT and S1P modulators underestimate JCV index value (26); using our assays to measure CD4 and CD8 cell-based immunity will allow one to more accurately predict PML risk and monitor for treatment response. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.